Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RWJ-333369 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Percent reduction in the average monthly migraine frequency from the baseline period to the entire double-blind treatment phase. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Johnson & Johnson Pharmaceutical R & D, L.L.C., Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northport | Alabama | United States | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19222595 | Derived | Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP; Study Group. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache. 2009 Feb;49(2):216-26. doi: 10.1111/j.1526-4610.2008.01326.x. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Phoenix |
| Arizona |
| United States |
| Little Rock | Arkansas | United States |
| Berkeley | California | United States |
| Golden | Colorado | United States |
| Miami | Florida | United States |
| St. Petersburg | Florida | United States |
| Chicago | Illinois | United States |
| Baton Rouge | Louisiana | United States |
| Brockton | Massachusetts | United States |
| Springfield | Massachusetts | United States |
| Chaska | Minnesota | United States |
| Springfield | Missouri | United States |
| Greensboro | North Carolina | United States |
| Bismarck | North Dakota | United States |
| Cincinnati | Ohio | United States |
| Mogadore | Ohio | United States |
| Nashville | Tennessee | United States |
| Austin | Texas | United States |
| Houston | Texas | United States |
| Lake Jackson | Texas | United States |
| Richardson | Texas | United States |
| Alexandria | Virginia | United States |
| Olympia | Washington | United States |
| Middleton | Wisconsin | United States |
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| D006261 | Headache |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C518914 | S-2-O-carbamoyl-1-o-chlorophenyl-ethanol |
Not provided
Not provided
Not provided